Feedback
Settings

Settings

Goto Application

22,525 results
Offices all Languages en Stemming true Single Family Member false Include NPL false
RSS feed can only be generated if you have a WIPO account

Save query

A private query is only visible to you when you are logged-in and can not be used in RSS feeds

Query Tree

Refine Options

Offices
All
Specify the language of your search keywords
Stemming reduces inflected words to their stem or root form.
For example the words fishing, fished,fish, and fisher are reduced to the root word,fish,
so a search for fisher returns all the different variations
Returns only one member of a family of patents
Include Non-Patent literature in results

Full Query

(ABE/hepatitis)%20

Side-by-side view shortcuts

General
Go to Search input
CTRL + SHIFT +
Go to Results (selected record)
CTRL + SHIFT +
Go to Detail (selected tab)
CTRL + SHIFT +
Go to Next page
CTRL +
Go to Previous page
CTRL +
Results (First, do 'Go to Results')
Go to Next record / image
/
Go to Previous record / image
/
Scroll Up
Page Up
Scroll Down
Page Down
Scroll to Top
CTRL + Home
Scroll to Bottom
CTRL + End
Detail (First, do 'Go to Detail')
Go to Next tab
Go to Previous tab

Analysis

1 / 2,253
1.104644661Application of 20(R)-ginsenoside Rg3 in preparation of medicament for relieving or/and treating hepatitis B and medicament
CN - 27.05.2015
Int.Class A61K 31/704
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
70Carbohydrates; Sugars; Derivatives thereof
7028Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
7034attached to a carbocyclic compound, e.g. phloridzin
704attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
 Appl.No 201410613655.6 Applicant FU LI Inventor LIU ZHENGXIAN
The invention discloses new application of 20(R)-ginsenoside Rg3 in preparation of a medicament for relieving or/and treating hepatitis B. Experiments prove that 20(R)-ginsenoside Rg3 has a significant effect of treating hepatitis B, can take effect rapidly, has low toxic or side effect, is a hepatitis B treating medicament which is safe, efficient, stable and simple to prepare, and is suitable for industrialized production and easy to popularize. According to the invention, a new medicament source for preventing and treating hepatitis B and complications thereof is provided.
2.105853444Application of 20(R)-panaxatriol derivative in preparing medicine for preventing or treating liver diseases
CN - 17.08.2016
Int.Class A61K 31/58
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
56Compounds containing cyclopentahydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
58containing heterocyclic rings, e.g. aldosterone, danazol, stanozolol, pancuronium, digitogenin
 Appl.No 201610334437.8 Applicant Nantong University Inventor Chen Guangtong
The invention discloses application of a 20(R)-panaxatriol derivative or pharmaceutically formable salt thereof in preparing a medicine for preventing or treating liver diseases. A microbial conversion technique is adopted for structural modification on 20(R)-panaxatriol, multiple novel compounds can be prepared, and in-vitro anti-hepatic fibrosis cell tests show that the compounds are very good in anti-hepatic fibrosis activity, can be used as active components of anti-hepatic fibrosis medicines, and have wide application.
3.02088664RECOMBINANT PLASMID DNA PDES 20 ENCODING THE SURFACE ANTIGEN OF HEPATITIS B VIRUS (HBSAG/AYW), THE YEAST STRAIN SACCHAROMYCES CEREVISIAE CONTAINING THE RECOMBINANT PLASMID DNA PDES 20 - A PRODUCER OF THE SURFACE ANTIGEN OF HEPATITIS B VIRUS (HBSAG/AYW)
RU - 27.08.1997
Int.Class C12N 15/51
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
11DNA or RNA fragments; Modified forms thereof
31Genes encoding microbial proteins, e.g. enterotoxins
33Genes encoding viral proteins
51Hepatitis viruses
 Appl.No 96101565/13 Applicant Aktsionernoe obshchestvo zakrytogo tipa nauchno-proizvodstvennaja kompanija "Kombiotekh Ltd." Inventor Drutsa V.L.
FIELD: medicinal biotechnology, genetic engineering, virology. SUBSTANCE: invention relates to preparing the recombinant plasmid DNA pDES 20 encoding synthesis of hepatitis B virus surface antigen (HBsAg/ayw), the yeast strain Saccharomyces cerevisiae DAN-041/pDES 20 producing HBsAg/ayw and vaccine based on thereof. Constructed recombinant plasmid DNA pDES 20 has gene HBsAg/ayw under control of the modified promoter region of the yeast gene PH05 that is able to independent replication in E. coli and S. cerevisiae cells. Strain S. cerevisiae DAN-041/pDES 20 is obtained at yeast cells transformation with recombinant plasmid pDES 20. Strain produces antigen HBsAg/ayw at expression level up to 5 mg/1 l culture and showing 100% stability of plasmid under nonselective growth conditions. Vaccine for hepatitis B control contains an effective amount of hepatitis B virus recombinant surface antigen (HBsAg/ayw), adjuvant, preserving agent, physiologically acceptable dilutant and shows high immunogenicity at minimal by-side reactive effect. EFFECT: recombinant plasmid DNA indicated above, high expression level of antigen. 3 cl
4.WO/2009/153261HYDROXYPHENYL-SUBSTITUTED PYRROLO[2,3d]PYRIMIDINE DERIVATIVES, PROCESSES AND INTERMEDIATE PRODUCTS FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THESE COMPOUNDS
WO - 23.12.2009
Int.Class C07D 487/04
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
 Appl.No PCT/EP2009/057473 Applicant ABBOTT PRODUCTS GMBH Inventor DE KANTER, Ruben
Novel compounds are described of the general formula (I), which are selective antagonists of the adenosine A1 receptor and wherein the substituents R1 have the meanings given in the description,and also medicaments containing these compounds, in particular medicaments suitable for treating or preventing cardio-vascular, renal, and/or hepatic disorders or diseases.
5.1207310Method of preparing capsule (pill) for treating hepatitis B
CN - 10.02.1999
Int.Class A61K 35/78
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
78Materials from plants
 Appl.No 98101781.9 Applicant Liu Fuzhong Inventor Liu Fuzhong
A medicine in the form of capsule or pill for treating hepatitis B, chronic hepatitis and hepatic hydroperitoneum is prepared from 20 Chinese-medicinal materials such as schisandra fruit, white peony root, cinammon twigs, etc through drying, pulverizing sieving, mixing, decocting, spray granulating and capsulizing, or mixing with honey and pilling, and features high curative effect, low cost and no toxic by-effect.
6.WO/2012/120044TFEB VARIANTS AND USES THEREOF
WO - 13.09.2012
Int.Class C07K 14/47
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
KPEPTIDES
14Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
435from animals; from humans
46from vertebrates
47from mammals
 Appl.No PCT/EP2012/053921 Applicant FONDAZIONE TELETHON Inventor SETTEMBRE, Carmine
The invention refers to TFEB related molecules, as variants, mutants, truncated proteins,chimeras etc. that are constitutively localized in the nucleus of a eukaryote cell. Such molecules have a therapeutic applicability in all of disorders that need of an induction of the cell authophagic/lysosomal system, as lysosomal storage disorders, neurodegenerative diseases, hepatic diseases, muscle diseases and metabolic diseases.
7.WO/2023/237728TREATING HEPATITIS
WO - 14.12.2023
Int.Class A61K 31/513
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
495having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
513having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
 Appl.No PCT/EP2023/065469 Applicant ALBIREO AB Inventor LINDSTRÖM, Erik
Provided herein are methods for treating hepatitis B and/or D with an Na+/taurocholate co-transporting polypeptide (NTCP) inhibitor such as a compound of formula (I), or a pharmaceutically acceptable salt thereof, or a compound of formula (II), or a pharmaceutically acceptable salt thereof. Such methods can include decreasing the concentration of hepatitis B DNA, decreasing the concentration of hepatitis D DNA, decreasing hepatitis B surface antigen, and decreasing hepatitis B core antigen (HBcAg).
8.108014146Preparation method of traditional Chinese medicine for treating hepatitis B and hepatic cirrhosis
CN - 11.05.2018
Int.Class A61K 36/074
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
06Fungi, e.g. yeasts
07Basidiomycota, e.g. Cryptococcus
074Ganoderma
 Appl.No 201610935874.5 Applicant GONG CHENGLONG Inventor THE INVENTOR HAS WAIVED THE RIGHT TO BE MENTIONED
The present invention belongs to a traditional Chinese medicine for treating hepatitis B and hepatic cirrhosis, the traditional Chinese medicine for treating hepatitis B and hepatic cirrhosis comprises, by weight, 5-20 parts of wild Ganoderma lucidum and 10-30 parts of wild Ganoderma applanatum, optimally 15 parts of the wild Ganoderma lucidum and 20 parts of the wild Ganoderma applanatum, and thewild Ganoderma lucidum and the wild Ganoderma applanatum are combined and matched in a certain proportion, so that immunity can be bettered improved, and replication of hepatitis B virus can be prevented.
9.101978999Medicament for treating icteric hepatitis
CN - 23.02.2011
Int.Class A61K 36/725
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
36Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
18Magnoliophyta (angiosperms)
185Magnoliopsida (dicotyledons)
72Rhamnaceae (Buckthorn family), e.g. buckthorn, chewstick or umbrella-tree
725Ziziphus, e.g. jujube
 Appl.No 201010503908.6 Applicant Zhen Fanbo Inventor Huang Ling
The invention relates to a medicament for treating icteric hepatitis. The medicament comprises 20 grams of astragalus, 30 grams of copperas, 10 grams of Szechwan chinaberry fruit, 30 grams of walnut kernel, 30 grams of jujube pulp and 30 grams of large-headed atractylodes rhizome; and the accuracy of the dosage of each medicament is +/-10 percent. The medicament for treating the icteric hepatitis has remarkable curative effect of treating the icteric hepatitis, particularly has remarkable effect of treating acute icteric hepatitis, and has quick response, safety and no toxic or side effect.
10.2008297204HEPATIC FIBROSIS-INHIBITING OR IMPROVING AGENT CONTAINING POLYLACTIC ACID MIXTURE
JP - 11.12.2008
Int.Class A61K 31/765
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
74Synthetic polymeric materials
765Polymers containing oxygen
 Appl.No 2007141264 Applicant MURAKAMI MASAHIRO Inventor MURAKAMI MASAHIRO

PROBLEM TO BE SOLVED: To provide a new hepatic fibrosis-inhibiting or improving agent by evaluating a hepatic fibrosis-inhibiting action exhibited by a cyclic and/or linear polylactic acid mixture.

SOLUTION: This hepatic fibrosis-inhibiting or improving agent contains a cyclic and/or linear polylactic acid mixture having a condensation degree of 3 to 20. The new hepatic fibrosis-inhibiting or improving agent, and foods and drinks using the hepatic fibrosis-inhibiting or improving agent can be provided by the present invention.

COPYRIGHT: (C)2009,JPO&INPIT

# -